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Abstract
Background: Dengue is a major public health problem in tropical and subtropical countries and has a presentation
similar to other febrile illnesses. Since laboratory confirmation is frequently delayed, the majority of dengue cases are
diagnosed based on symptoms. The objective of this study was to identify clinical, hematological and demographical
parameters that could be used as predictors of dengue fever among patients with febrile illness.
Methods: We conducted a retrospective cohort study of 548 patients presenting with febrile syndrome to the largest
public hospitals in Honduras. Patients’ clinical, laboratory, and demographic data as well as dengue laboratory detection
by either serology or viral isolation were used to build a predictive statistical model to identify dengue cases.
Results: Of 548 patients, 390 were confirmed with dengue infection while 158 had negative results. Univariable analysis
revealed seven variables associated with dengue: male sex, petechiae, skin rash, myalgia, retro-ocular pain, positive
tourniquet test, and gingival bleeding. In multivariable logistic regression analysis, retro-ocular pain petechiae and gingival
bleeding were associated with increased risk, while epistaxis and paleness of skin were associated with reduced risk of
dengue. Using a value of 0.6 (i.e., 60% probability for a case to be positive based on the equation values), our model had
a sensitivity of 86.2%, a specificity of 27.2%, and an overall accuracy of 69.2%; allowing for the diagnosis of dengue to be
ruled out and for other febrile conditions to be investigated.
Conclusions: Among Honduran patients presenting with febrile illness, our analysis identified key symptoms associated
with dengue fever, however the overall accuracy of our model was still low and specificity remains a concern. Our model
requires validation in other populations with a similar pattern of dengue transmission.
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Background
Dengue is a vector-borne flavivirus infection transmitted
by Aedes mosquitoes that poses a major public health
threat in many tropical and subtropical regions [1–3].
Worldwide, dengue affects 50 million people annually and
causes 20,000 to 25,000 deaths [1]. In Honduras, 66,814
cases were reported in 2010, with a case fatality rate of 3%
[4]. Dengue cases in Honduras are concentrated in urban
centers where the affected populations include both
school age children and adults. In recent years the inci-
dence has peaked between June and November, with
epidemics observed every 24 to 36 months [4].
Clinical manifestations of dengue range from febrile ill-
ness to severe complications resulting in hospitalization
and death. In its early stages, dengue resembles other
febrile illness such as malaria, influenza, and leptospirosis,
constituting a diagnostic challenge for clinicians in
endemic countries [5]. Further complications to dengue
diagnosis arise from the presence of overlapping manifes-
tations such as the presence of hematuria, which can
occur in cases of either falciparum malaria or dengue
[6, 7]. The ability to differentiate between dengue and
other conditions is of prime importance to clinicians in
dengue endemic areas. An early diagnosis allows for the
early monitoring of indicators that are associated with
eventual severe disease.
A confirmatory diagnosis of dengue is made through
laboratory diagnosis using serology (e.g., IgM titres, IgG
seroconversion), antigen detection of non-structural
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protein (NS) in sera, or polymerase chain reaction (PCR)
for dengue virus nucleic acids in blood. Of these labora-
tory methods, PCR is not available in many middle and
low income countries. Similarly, antigen detection of NS
is frequently unavailable or is not part of routine dengue
confirmation. Although serology is available in many set-
tings, there may be delays in obtaining results, and, in
many areas, no laboratory testing is available at all.
Although there is no specific therapy, identifying den-
gue can help clinicians make better decisions; for
example they can triage patients by knowing which
patients need to be monitored for possible dengue com-
plications. On the other hand, dengue diagnosis based
solely on clinical presentation is challenging and can
lead to misdiagnosis with the ensuing consequences for
patients. In Honduras, for example, studies show that
less than 50% of specimens tested in cases of suspected
dengue are confirmed to be positive, with the remainder
being negative or inconclusive [8, 9].
Previous reports exist of models for dengue, using
symptoms, signs, and laboratory data to differentiate
dengue from other febrile syndromes [10–16]. Demo-
graphic factors such as age and sex [12, 13]; clinical
symptoms such as joint pain, vomiting, and myalgia
[15]; and laboratory findings such leucopenia and
thrombocytopenia [16], have all been reported as pre-
dictors for dengue. Limitations of these studies include
a small sample size [11–14], lack of validation of the
models [17], limited geographic representation [14, 15],
and limited predictive ability of the results [17–19].
We conducted analyses using data that was system-
atically collected on a cohort of febrile patients seen
at different health care facilities in Honduras. Using
these data, we built and validated logistic regression
models to identify clinical factors to predict labora-
tory confirmed dengue.
Methods
Data on signs and symptoms of patients who present
with dengue is routinely collected in Honduras and
submitted to the Honduran National Classification
Committee for classification of cases. We used such data
collected between June 2009 and June 2010 from
patients who presented with fever and ≥ 2 symptoms to
one of five hospitals and outpatient clinics located in
Tegucigalpa and San Pedro Sula, the two largest cities in
Honduras. These symptoms included headache, retro-
ocular pain, myalgia, rash, anorexia and vomiting, any
bleeding manifestation, including petechiae, ecchymosis,
epistaxis, gingival bleeding, hematuria, heavy menstrual
bleeding, and symptoms suggestive of capillary leakage,
including abdominal pain, cold extremities, and sweat-
ing. Patients of all ages were included in our analyses, all
were tested for dengue and all, if not hospitalized at
presentation, were subsequently hospitalized. Patients
were seen either at healthcare facilities that are part of
the social security system (Instituto Hondureño de
Seguridad Social) or not facilities that form part of the
public health system. The former serves the insured
employed population whereas the latter serves the gen-
eral population with no restrictions.
General practitioners, nurses, and microbiologists at
either the primary health care centres or at the ter-
tiary hospitals completed a data collection form (for
case classification) which included epidemiological
and clinical information. Symptoms and signs were
collected at first presentation while hematology and
biochemical tests recorded were those at presentation
and those repeated approximately one week later.
Fever was defined as a temperature of > 37.5 degrees
Celsius. Both objective measurements of fever and
self-report of fever were included. Conditions with a
febrile presentation, such as malaria, kidney infec-
tions, chronic hepatitis, leptospirosis, and respiratory
infections were evaluated however complete informa-
tion on the ultimate diagnosis for patients that tested
negative for dengue was either not available or not
recorded in the data collection form.
Blood samples were collected from patients for dengue
laboratory confirmation. If a patient presented within 5
days of the first symptom onset, samples were processed
for viral culture following guidelines from the U.S Cen-
ters for Disease Control and Prevention (CDC) [20]. If
the blood sample was taken on the sixth day or later of
onset of symptoms, a test for antibody detection was
done using IgM antibody-capture enzyme-linked im-
munosorbent (IgM Mac ELISA) from Standard Diagnos-
tic of Bio Venture Company (Gyeonggi-do, South Korea)
[20, 21]. This commercial kit reports a sensitivity of
96.4% and specificity of 98.9% [21]. Serology and viral
isolation were performed at the Honduras National
Laboratory of Virology according to CDC guidelines and
standardized techniques.
For hospitalized patients, our analysis was based on
serial blood tests taken over the 3 days following admis-
sion, and using additional radiological or laboratory
testing if available. The initial clinical diagnosis of the
treating physician prior to laboratory confirmation was
recorded and submitted to the Honduran National
Classification Committee for classification as uncompli-
cated dengue or severe dengue i.e. dengue haemorrhagic
fever or shock syndrome [8, 22].
All patients received a laboratory result for dengue
(either positive or negative based on viral isolation or
IgM). Complete information was obtained for 548
patients. Of 548 patients studied, 390 had laboratory
evidence for dengue infection while 158 had negative
results.
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Predictor variables
We used the data collected at presentation to assess
predictor variables for dengue by grouping these into
three categories: 1) general symptoms, including fever,
headache, retro-ocular pain, myalgia, rash, anorexia and
vomiting; 2) bleeding manifestations, including pe-
techiae, ecchymosis, hematemesis, melena, positive
tourniquet, epistaxis (nose bleeding), gingival bleeding,
hematuria, and heavy menstrual bleeding (metrorrha-
gia); and 3) symptoms and signs suggestive of capillary
leakage, including abdominal pain, cold extremities,
sweating, paleness of skin, serous membranes’ effusion
(pericardial, pleural effusion and ascites), and reduction
of mean arterial pressure. Hematological results (leuco-
cytes count, and hemoglobin and hematocrit values)
were recorded if they were available for at least two
consecutive days.
Power calculation
A sample size was not determined a priori since the
study enrolled all patients admitted during the study
period who had febrile illness and laboratory testing for
dengue. Since petechiae are both readily identifiable and
are commonly seen in dengue infection we based the
study’s power calculation on the predictive value of
petechiae to differentiate dengue from other febrile ill-
ness [23]. Based on the 548 records (390 dengue-positive
and 158 dengue-negative), assuming a prevalence of
petechiae of 25% in non-dengue febrile illness and an
alpha level of 0.05, the study had 80% power to detect a
1.5-fold increase risk of dengue given the presence of
petechiae.
Data analysis
The chi-square test was used to detect significant differ-
ences between presenting signs and symptoms (recorded
during admission and on the first day of the patient’s
stay, prior to being tested for dengue) and the laboratory
tests results.
A logistic regression model was built using a forward
step-wise selection. Variables with p < 0.2 were entered
into the multivariable models. We decided a priori to
include both age and sex in the analysis. Correlation
among pairs of variables was assessed calculating values
for tolerance and the variance inflation factor (VIF).
Values for tolerance >0.2 and for VIF < 5 were consid-
ered as being compatible with a low collinearity. Vari-
ables that were statistically significant (p < 0.05) were
kept in the final model.
Confidence intervals for the odds ratios, were calcu-
lated for each predictor. As part of the models’ internal
validation, the bootstrap method (i.e. resampling data)
was used to estimate the accuracy of the estimators
(standard error, confidence intervals and bias) [24–26].
The model was also validated using subsamples, each
corresponding to one tenth of the sample and with nine
tenths of the remaining sample used for a cross-
validation. The subsamples were drawn using systematic
sampling (including every tenth case for each subsample)
without leaving any patient out of the procedure.
Additionally, as a sensitivity analysis, we created a
dichotomous variable for the type of health care facility
where patients had presented to either the social security
system (accessible only to the insured employed popula-
tion) or at public health clinics (open to the general
population). This was done to account for potential
centre effect, that is, differences between the two patient
populations.
After building and validating logistic regression
models, the sensitivity of the method was determined
using the receiver operating characteristic (ROC) curve,
which is a graphic plot illustrating the performance of a
binary classifier system like the one used during this
study.
Using the model equation, we then created a score
from the equation by transforming the values assigned
to each predictor to integers by multiplying by ten
(avoiding decimal values). All statistical analysis were
done using SPSS version 19 (IBM) [27].
Results
The final study sample consisted of 548 patients: 227
were female (41%); mean age 21 years of age (SD =
15.5 years). Of these patients, 295 (53.8%) were admitted
to tertiary-level hospitals, 240 (43.8%) in hospitals pro-
viding care for insured workers, and 13 (2.4%) originally
seen in regional and local health clinics and later admit-
ted to hospital.
Complete clinical and demographic data was available
for all 548 patients. However, information on the date of
onset of symptoms was missing in 10% of the sample.
The duration of signs or symptoms from date of onset is
summarized in Table 1. For 495 patients for whom the
date of onset of symptoms was available, the mean time
for obtaining the dengue sample from onset of symp-
toms was 6 days (range 0–65 days).
Viral isolation by cell culture was done in 114 patients
who presented within the first 5 days of symptoms,
resulting in 9 (7.9%) positive isolates. Serology was done
in the remaining 434 patients, 381 (87.8%) of whom
were seropositive. Altogether, dengue laboratory testing
revealed that 390 patients (71%) were positive (381 by
serology and 9 by viral isolation).
The social security system submitted 239 blood sam-
ples and 203 (84.9%) tested positive. The public health
system submitted 309 samples and 187 (60.5%) tested
positive. In terms of type of test requested, viral isolation
was requested in 14 patients by the social security
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system and in 100 patients by the public health system,
for a positivity of 28.6% (five cases) and 5% (five cases) re-
spectively. Antibody determination was requested for 225
patients by the social security system and for 209 patients
by the public health system, for a positivity of 88.4% (199
patients) and 87.1% (182 patients), respectively.
The mean hematocrit was 40.6 with a range from 17.4
to 40.6 while the mean platelet count at admission was
74,311 with a range from 113 to 61,600. The mean
leukocyte count was 5066 (range 513 to 36,000).
Nine variables (petechiae, skin rash, myalgias, retro-
ocular pain, tourniquet test, cold limbs, gingival bleed-
ing, epistaxis, and skin paleness) had a p value < 0.2 and
were thus considered for multivariable analysis (Table 2).
The following variables were independently associated
with dengue in multivariable analysis: petechiae (OR 2.0,
95% CI: 1.3, 3.3), retro-ocular pain (OR 1.7, 95% CI: 1.1,
2.5), gingival bleeding (OR 3.7, 95% CI: 1.1, 13), epistaxis
(OR 0.6, 95% CI: 0.4, 1.0), and skin paleness (OR 0.6, 95%
CI: 0.4, 0.9) (Table 3). Statistics for collinearity were also ap-
plied and the values for tolerance were >0.7 and the VIF
(variance inflation factor) was ≤1.3, which represent no sig-
nificant collinearity among variables tested in the model.
The model had a sensitivity of 86.2% and a specificity
of 27%, with a positive predictive value of 74.5% and a
negative predictive value of 44.3%. The positive and
negative likelihood ratios were 1.2 and 0.5, respectively,
for an overall model accuracy of 69.2%. For the classifi-
cation of cases (positive cases), the software’s default
threshold or cut-point was 0.5; however the specificity
was extremely low (4.4%). Therefore, we increased the
cut-point to 0.6 which reduced the overall model predic-
tion (from 71.9 to 69.2%) but increased the specificity. In
this cases the cut-point defined the level of acceptance
of the cases as positive dengue, ROC was used to iden-
tify the best cut-point for the classification that provided
a higher specificity while keeping a level of sensitivity
higher than 85%.
Applying the bootstrap method, we found that p values
from the subsamples were similar to those obtained in the
entire sample, and the bias values were < 25% of the stand-
ard error values of the predictors of the subsamples.
Including the health care facility as a variable in the
multivariable analysis, as a sensitivity analysis, yielded a
model that included two clinical predictors with a positive
association to confirmed dengue: petechiae (OR 1.80; 95%
CI: 1.11 to 2.92) and gingival bleeding (OR 3.24,95% CI:
0.93,11.26). It also revealed paleness of skin as a negative
association (OR 0.61; 95% CI: 0.41, 0.90). The health care
facility was also a significant predictor for dengue (OR
3.42; 95%CI: 2.23, 5.26). Retroocular pain and epistaxis did
not appear in this model and the odds ratios for the clin-
ical predictors in this model had smaller odds ratios. At a
cut point of 0.6, this alternative model correctly classified
69.9% of the patients, with a sensitivity of 84.1% and speci-
ficity of 34.8%, representing a slight improvement in over-
all classification and specificity but with a reduction in
sensitivity over the previous model based only on clinical
signs and symptoms. The model, which included health
care facility, was also validated using the bootstrap test
(data not shown). (Table 4).
Table 1 Duration of signs and symptoms from date of onset of
study patients
0–3 days 4–6 days ≥7 days
N (%) N (%) N(%)
Fever 54(100) 262(98.5) 172(98.3)
Headache 47(87.0) 229(86.1) 147(84.2)
Retroocular Pain 39(72.2) 200(75.2) 125(71.4)
Myalgias 46(85.2) 222(83.5) 151(86.3)
Arthralgias 40(74.1) 193(72.6) 136(77.7)
Skin rash 19(35.2) 92(34.6) 59(33.7)
Anorexia 38(70.4) 218(82.0) 142(81.1)
Petechiae 7(13.0) 73(27.4) 61(34.9)
Epistaxis 9(16.7) 53(19.9) 32(18.3)
Echymoses 1(1.9) 21(7.9) 21(12.0)
Gingival bleeding 2(3.7) 14(5.3) 9(5.1)
Pallor 25(46.3) 123(46.2) 86(49.1)
Table 2 Variables associated with laboratory confirmed dengue






Male 168 (43.5) 1.28 (0.9 to 1.8) 0.20
Petechiae 120 (81.1%) 1.52 (1.0 to 2.3) 0.002
Skin rash 138 (76.7) 1.51 (1.0 to 2.3) 0.046
Myalgia 336 (72.6) 1.52 (0.93 to 2.47) 0.09
Retroocular pain 296 (74.6) 1.51 (1.0 to 2.3) 0.04
Positive Tourniquet test 26 (86.7) 2.75 (0.94 to 8.0) 0.05
Cold limbs 139 (66.8) 0.71 (0.5 to 1.0) 0.08
Gingival bleeding 24 (88.9) 3.4 (1.0 t 11.4) 0.04
Epistaxis 68 (63.6) 0.64 (0.41 to 1.01) 0.06
Paleness 174 (65.9) 0.61 (0.4 to 0.9) 0.009
Table 3 Final logistic regression model for predictors of dengue
Variable Odds ratio (95% CI) P value
Petechiae 2.0 (1.3 to 3.3) 0.003
Retroocular pain 1.7 (1.1 to 2.5) 0.01
Gingival bleeding 3.7 (1.1 to 13.0) 0.04
Epistaxis 0.6 (0.4 to 1.0) 0.045
Paleness 0.6 (0.4 to 0.9) 0.006
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In the analysis of ROC we found that the area under
the curve was 0.663 (asymptotic 95% CI: 0.616, 0.710).
The equation for the model was y = 0.694 + 0.718(pe-
techiae) + 0.516 (retro-ocular pain) + .316(gingival bleed-
ing) – 0.474 (epistaxis)- 0.535 (skin paleness). The
results given by the ROC curve showed a logistic regres-
sion model with an area under the curve (AUC) of 0.65
(95% CI = 0.60, 0.70) and a standard error of 0.025, being
statistically significant. The logistic regression model had
a good overall prediction and this was confirmed
through the ROC analysis.
Using the equation, a score was obtained by rounding
up values of the equation to the close integer, with the
next values. Therefore, petechiae = 7, retroocular pain =
5, gingival bleeding = 13 (all when the sign is present)
and epistaxis = −5 and skin paleness = −5 (negative
values for when they are present). When only positive
predictors are present, the maximum score would be 25
whereas when only negative predictors are present the
score would be −10. Intermediate values can be obtained
with different combination of predictors.
The score was simplified using the values of the equa-
tion and reducing it to values 0 and 1 assigning 1 to
those considered cases and 0 to non-cases. That is, signs
and symptoms scores were added and a threshold value
of 3 was selected to differentiate cases from non cases,
(any value ≤ 3 was coded as 0 and values >3 were coded
as 1). This resulted in 336 of the 390 positive correctly
predicted, and 43 of the 158 negative patients predicted
as no dengue cases. The sensitivity and specificity for
this score were 86.2% and of 27%, respectively. The area
under the curve was 0.567(asymptotic 95% CI were
0.512, 0.622) with a standard error of 0.028. The accur-
acy is still low if is intended to operationalize the equa-
tion for clinical personnel providing a rapid method to
identify cases of dengue.
Discussion
Our logistic regression model found that five symptoms
or signs helped differentiate dengue from other febrile
illness: [1] petechiae, [2] retro-ocular pain, [3] gingival
bleeding, [4] epistaxis and [5] skin paleness. Of these,
the association was positive for the first three (likely to
be present in dengue cases), and negative for the last
two (epistaxis and pale skin), consistent with being less
likely to be present in dengue cases.
Our analysis used similar variables to that of previous
reported models, but in contrast to previous reports, we
not only built and validated a model but created scoring
system to assess the model. A cross-sectional study to
differentiate dengue from non-dengue among patients
attending the emergency department of a public hospital
in Brazil was described in one report (10). Only conjunc-
tival redness and leukocyte count were associated with
dengue. The sensitivity and specificity of this model was
80.8 and 71.1% respectively but did not include valid-
ation techniques. Ramos et al. used surveillance data
from Puerto Rico and reported that rash and either the
absence of sore throat, nasal congestion, or cough had
low (<50%) sensitivity for ruling out dengue in children
(11). However, validation and construction of a predict-
ive rule was not conducted. In another study from
Puerto Rica using surveillance data, five variables (retro-
orbital pain, rash, low platelet count, lack of sore throat,
absence of cough) were used to build models that had
AUC of 0.76. However, a cut-off point for diagnostic ac-
curacy was not reported (13). In a study from Papa New
Gunia, only facial flushing and male sex were associated
with dengue in multivariable analysis (14). The AUC was
0.59 but no cut-off was used to predict cases. In a study
from Nicaragua among children, fever, headache, retro-
orbital pain, myalgia, arthralgia, rash, petechiae, positive
tourniquet test, vomiting, leukopenia, platelets ≤150,000
cells/mL, poor capillary refill, cold extremities and hypo-
tension.were associated wtth dengue. This study did not
use the model to predict dengue in a validation set.
Including clinical signs in the model make intuitive
sense and we consider it to be a strength. Petechiae and
gingival bleeding, for example, represent subcutaneous
or mucosal bleeding and are therefore readily noticeable
by the patient and reported as such. Epistaxis can be fre-
quently associated with respiratory conditions rather
than with dengue, and in our sample most patients with
epistaxis had a negative dengue test.
With respect to effect size, gingival bleeding had a
higher odds ratio than other predictors but also had a
wider confidence interval (OR 3.7, CI: 1.1, 13.0.)
followed by petechiae, retro-ocular pain. Compared to
other studies, our odds ratios were smaller for pe-
techiae, retro-orbital pain and gingival bleeding but
clearly represented a positive association with dengue
positivity [10, 23, 28–34].
Unlike other studies that have found epistaxis and skin
paleness positively associated with dengue [3, 10, 32, 34],
our study identified an inverse association with both.
Most of our patients with epistaxis had a negative den-
gue result. Mittal et al. reported that skin paleness or
pallor was associated with advanced stages of dengue. In
Table 4 Logistic regression model including health system
Variable Odds ratio (95% CI) P value
Petechiae 1.8 (1.1 to 2.9) 0.02
Gingival bleeding 3.2 (0.93 to 11.3) 0.06
Health system 3.4 (2.2 to 5.3) <0.001
Paleness 0.6 (0.4 to 0.9) 0.01
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fact, 13.3% of their patients with dengue were described
as having pallor [34].
Paleness of skin has been found associated to dengue
presumably because of vascular events (bleeding, vaso-
constriction) occurring when dengue evolves into severe
forms. In Central America, as in other developing
regions, paleness can be associated with chronic anemia
and malnutrition but frequently the clinician is faced
with limited laboratory resources and must resort to
basic clinical evaluation to make a diagnosis.
Notably, proportionally more patients from the social
security system hospitals were diagnosed correctly
(84.9%) than those from the public health system
(60.5%) as described in the results. The most likely
explanation is that there were proportionately more pa-
tients in the public health system that had specimens
sent for viral isolation at later time points (beyond
3 days) and that this resulted in a lower detection rate.
The model that included health care facility reduced
the number of symptoms to three: petechiae, gingival
bleeding and paleness of skin, keeping the same direc-
tion of association and similar effect size as the model
without health system. The sensitivity of the model in-
creased slightly to 84.1%, and the specificity to 34.8%,
for an overall accuracy of 69.9%. Including the health
care facility as a predictor increased the accuracy of the
model but resulted in a reduction in the number of clin-
ical predictors. Although this finding may suggest differ-
ences in the populations receiving care at different levels
of the Honduran health system, it is most probably due
to differences in the clinical judgment of treating physi-
cians at those levels.
A strength of this study is that it was conducted
during a period of active dengue transmission allowing
for a sufficient number of patients to be assessed. One
limitation is that our sample may have been character-
ized by an overrepresentation of symptoms deemed
important to a subgroup of patients in the early stages
of the syndrome, particularly with respect to pain (e.g.
headache, retro-ocular pain). Also, the difference in the
clinical diagnostic accuracy between health care facilities
providing information is a factor to consider as this may
represent different levels of experience with the disease.
Another potential limitation is that our study was con-
ducted when other viruses, such as Chikungunya and
Zika, were not circulating. There is a possibility that this
would have affected the predictive value of our model.
Since we conducted an analysis using a database on
suspected dengue, we did not have access to the final
diagnosis of non-dengue cases.
Prior laboratory data in Honduras shows that around
40% of suspected cases with confirmed to be positive by
laboratory testing [8, 9]. An important limitation of our
study is that IgM testing was not conducted on all
samples on days 4 and 5 [35]. We were also unable to dif-
ferentiate between primary and secondary dengue and this
could have affected results because of the predominance
of different symptoms in primary versus secondary den-
gue. The fact that most patients were admitted after 5
days following symptom onset may limit generalizability.
It is possible that our sample may have been biased by
spectrum, with a representation of patients with more se-
vere illness including symptoms of more severe disease
which is observed in patients consulting the medical ser-
vice but not in the community where milder disease is
more frequent. The retrospective nature of our study is
another limitation. To confirm the utility of this model it
should be tested both during epidemic and inter-epidemic
periods.
Conclusions
In conclusion, we demonstrate that a simple model may
identify useful predictors to differentiate between dengue
and other causes of febrile illness. The model should
optimally be used with a method for rapid confirmatory
testing. The use of such a model can define those cases
more likely to be dengue and needing primarily a dengue
test while other patients can be directed to a different
management. The use of a score table as the one pre-
sented in the results can facilitate the effort of those
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